Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
NCT02670707
Recruiting
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body,... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/01/2024
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Improving the Quality of Dementia Care Through Innovative Redesign of the Memory Care Environment
NCT04350060
Recruiting
Research study is being done to demonstrate novel opportunities to transform the way the dementia community is cared for.
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
07/29/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Dementia
Register for Updates
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study
NCT06511388
Recruiting
This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Sarcoma
Register for Updates
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
NCT06496217
Recruiting
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2024
Locations: MBX Biosciences Investigational Site, Minneapolis, Minnesota
Conditions: Renal Impairment
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
NCT05785819
Recruiting
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Register for Updates
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
NCT05459233
Recruiting
Data on valve performance following ViV-TAVR has usually been obtained with the use of Doppler-echocardiography. However, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. Thus, the incidence of procedural-device failure may be lower than that reported in the ViV-TAVR literature,
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Aortic Valve Stenosis, Aortic Valve Regurgitation, Prosthesis Failure
Register for Updates
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
NCT05399277
Recruiting
Transradial access (TRA) is the preferred vascular access site for invasive coronary angiography. TRA is limited by blockage of the radial artery post-procedurally, preventing future use of TRA. This is referred to as radial artery occlusion (RAO) and occurs in \~5% of cases. While intraprocedural anticoagulation has been studied extensively to mitigate this complication, oral anticoagulation post-TRA has not. The investigators will assess the impact of a one-week course of rivaroxaban post-TRA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Radial Artery Occlusion
Register for Updates
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
NCT06271577
Recruiting
AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagn... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Vascular Diseases, Heart Attack, Heart Failure
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Endometrial Cancer
Register for Updates
TMS + Exposure Therapy for Pediatric OCD
NCT05931913
Recruiting
The goal of this clinical trial is to compare different forms of transcranial magnetic stimulation (TMS) for improving the outcomes of Exposure with Response Prevention (ERP) in youth and young adults with Obsessive-Compulsive Disorder (OCD). Researchers will compare three groups: ERP with one of two different active ("real") forms of TMS vs. ERP with sham ("fake") TMS. The main questions this study aims to answer are: 1) whether TMS normalizes functioning in brain circuits that contribute to co... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
07/01/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Riverwood Healthcare Center, Aitkin, Minnesota
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates